Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.

ABSTRACT:

SUBMITTER: Harrington P 

PROVIDER: S-EPMC9024068 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature